<code id='36BEF6C408'></code><style id='36BEF6C408'></style>
    • <acronym id='36BEF6C408'></acronym>
      <center id='36BEF6C408'><center id='36BEF6C408'><tfoot id='36BEF6C408'></tfoot></center><abbr id='36BEF6C408'><dir id='36BEF6C408'><tfoot id='36BEF6C408'></tfoot><noframes id='36BEF6C408'>

    • <optgroup id='36BEF6C408'><strike id='36BEF6C408'><sup id='36BEF6C408'></sup></strike><code id='36BEF6C408'></code></optgroup>
        1. <b id='36BEF6C408'><label id='36BEF6C408'><select id='36BEF6C408'><dt id='36BEF6C408'><span id='36BEF6C408'></span></dt></select></label></b><u id='36BEF6C408'></u>
          <i id='36BEF6C408'><strike id='36BEF6C408'><tt id='36BEF6C408'><pre id='36BEF6C408'></pre></tt></strike></i>

          focus

          focus

          author:focus    Page View:7513
          Joaquin Duato -- health policy coverage from STAT
          Johnson & Johnson CEO Joaquin Duato MICHAEL BUHOLZER/AFP via Getty Images

          WASHINGTON — Merck CEO Robert Davis and Johnson & Johnson CEO Joaquin Duato have agreed to voluntarily testify before the Senate health committee, avoiding a threatened subpoena, the committee announced Friday.

          The decision by the executives came after a public pressure campaign by Sanders to get the two executives and Bristol Myers Squibb CEO Chris Boerner to testify about why prices for their drugs are higher in the United States than in other countries. Sanders had scheduled a vote to subpoena the Merck and Johnson & Johnson CEOs on Jan. 31, but canceled it on Friday.

          advertisement

          “​​The use of a subpoena was clearly a last resort and I’m delighted that these CEOs will be coming into our committee voluntarily,” Sanders said in a written statement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          Ultragenyx gene therapy for rare liver ailment succeeds in late
          Ultragenyx gene therapy for rare liver ailment succeeds in late

          JonathanWiggs/GlobeStaffUltragenyxsaidThursdayafternoonthatitsgenetherapyforarareliverailment,glycog

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

          2:42PresidentJoeBidenspeaksintheEastRoomoftheWhiteHouseinWashington,July25,2023.SusanWalsh/APPreside